{
  "company": {
    "name": "Nouscom",
    "website": "https://nouscom.com/",
    "record": "https://startuphistory.org/c/nouscom.com"
  },
  "status": null,
  "history_since": null,
  "baseline": null,
  "live_captures": 0,
  "last_checked": null,
  "live_status": "offline",
  "messaging": [],
  "changes": [],
  "update": null,
  "same_space": [
    {
      "name": "Infinitopes",
      "record": "https://startuphistory.org/c/infinitopes.com",
      "basis": "ai_judged",
      "category": null,
      "overlap": "direct",
      "why": "Both develop off-the-shelf viral-vector cancer vaccines to induce strong anti-tumor T-cell responses."
    },
    {
      "name": "VLP Therapeutics",
      "record": "https://startuphistory.org/c/vlptherapeutics.com",
      "basis": "ai_judged",
      "category": null,
      "overlap": "direct",
      "why": "Both design therapeutic cancer vaccines using virus-based platforms to treat tumors."
    },
    {
      "name": "Epitopea",
      "record": "https://startuphistory.org/c/epitopea.com",
      "basis": "ai_judged",
      "category": null,
      "overlap": "partial",
      "why": "Both create off-the-shelf cancer vaccines targeting shared tumor antigens to drive anti-tumor immunity."
    },
    {
      "name": "Oncorus",
      "record": "https://startuphistory.org/c/oncorus.com",
      "basis": "ai_judged",
      "category": null,
      "overlap": "partial",
      "why": "Both use viral and RNA platforms to develop systemic cancer immunotherapies."
    },
    {
      "name": "Omios Bio",
      "record": "https://startuphistory.org/c/omiosbio.com",
      "basis": "ai_judged",
      "category": null,
      "overlap": "partial",
      "why": "Both engineer viral platforms for cancer immunotherapy including oncolytic virus approaches."
    },
    {
      "name": "Candel Therapeutics",
      "record": "https://startuphistory.org/c/candeltx.com",
      "basis": "ai_judged",
      "category": null,
      "overlap": "partial",
      "why": "Both develop viral immunotherapies that expose tumor neoantigens and stimulate anti-tumor immune responses."
    },
    {
      "name": "Genelux Corporation",
      "record": "https://startuphistory.org/c/genelux.com",
      "basis": "ai_judged",
      "category": null,
      "overlap": "partial",
      "why": "Both use vaccinia-based viral platforms for oncolytic immunotherapies against solid tumors."
    },
    {
      "name": "Enterome",
      "record": "https://startuphistory.org/c/enterome.com",
      "basis": "ai_judged",
      "category": null,
      "overlap": "partial",
      "why": "Both develop off-the-shelf cancer immunotherapies that elicit durable anti-tumor T-cell responses."
    }
  ],
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Nouscom” company record, https://startuphistory.org/c/nouscom.com"
}